Department of Chemistry, Faculty of Science, Assiut University; Assiut 71516, Egypt.
Laboratory of Immunology, Zoology Department, Faculty of Science, Assiut University, Assiut 71516, Egypt.
Bioorg Chem. 2020 Mar;96:103569. doi: 10.1016/j.bioorg.2020.103569. Epub 2020 Jan 15.
A novel series of (Z)-3,5-disubstituted thiazolidine-2,4-diones 4-16 has been designed and synthesized. Preliminary screening of these compounds for their anti-breast cancer activity revealed that compounds 5, 7, and 9 possess the highest anti-cancer activities. The anti-tumor effects of compounds 5, 7, and 9 were evaluated against human breast cancer cell lines (MCF-7 and MDA-MB-231) and human breast cancer cells. They were also evaluated against normal non-cancerous breast cells, isolated from the same patients, to conclude about their use in a potential targeted therapy. Using MTT uptake method, these three compounds 5, 7, and 9 blunt the proliferation of these cancer cells in a dose-dependent manner with an IC of 1.27, 1.50 and 1.31 µM respectively. Interestingly, using flow cytometry analysis these three compounds significantly mediated apoptosis of human breast cancer cells without affecting the survival of normal non-cancerous breast cells that were isolated from the same patients. Mechanistically, these compounds blunt the proliferation of MCF-7 breast cancer cells by robustly decreasing the phosphorylation of AKT, mTOR and the expression of VEGF and HIF-1α. Most importantly, compounds 5, 7, and 9 without affecting the phosphorylation and expression of these crucial cellular factors in normal non-cancerous breast cells that were isolated from the same patients. Additionally, using Western blot analysis the three compounds significantly (P < 0.05) decreased the expression of the anti-apoptotic Bcl-2 members (Bcl-2, Bcl- and Mcl-1) and increased the expression of the pro-apoptotic Bcl-2 members (Bak, Bax and Bim) in MCF-7, MDA-MB-231 and human breast cancer cells making these breast cancer cells susceptible for apoptosis induction. Taken together, these data provide great evidences for the inhibitory activity of these compounds against breast cancer cells without affecting the normal breast cells.
设计并合成了一系列新型的(Z)-3,5-二取代噻唑烷-2,4-二酮 4-16。对这些化合物进行初步的抗乳腺癌活性筛选发现,化合物 5、7 和 9 具有最高的抗癌活性。评估了化合物 5、7 和 9 对人乳腺癌细胞系(MCF-7 和 MDA-MB-231)和人乳腺癌细胞的抗肿瘤作用。还评估了它们对同一患者来源的正常非癌细胞的作用,以得出关于它们在潜在靶向治疗中的应用的结论。使用 MTT 摄取法,这三种化合物 5、7 和 9 以剂量依赖的方式抑制这些癌细胞的增殖,IC 分别为 1.27、1.50 和 1.31µM。有趣的是,使用流式细胞术分析,这三种化合物显著介导了人乳腺癌细胞的凋亡,而不影响同一患者来源的正常非癌细胞的存活。从机制上讲,这些化合物通过强烈降低 AKT、mTOR 的磷酸化以及 VEGF 和 HIF-1α 的表达来抑制 MCF-7 乳腺癌细胞的增殖。最重要的是,化合物 5、7 和 9 不影响同一患者来源的正常非癌细胞中这些关键细胞因子的磷酸化和表达。此外,使用 Western blot 分析,这三种化合物显著(P<0.05)降低了 MCF-7、MDA-MB-231 和人乳腺癌细胞中抗凋亡 Bcl-2 成员(Bcl-2、Bcl-xL 和 Mcl-1)的表达,并增加了促凋亡 Bcl-2 成员(Bak、Bax 和 Bim)的表达,使这些乳腺癌细胞易受凋亡诱导。综上所述,这些数据为这些化合物抑制乳腺癌细胞而不影响正常乳腺细胞的活性提供了充分的证据。